Ultra-Low Dose IL-2 Therapy as GVHD Prophylaxis in Haploidentical Allogeneic Stem Cell Transplantation

Clinical trial NCT02226861 · COMPLETED

Trial details

NCT number: NCT02226861
Sponsor: National Heart, Lung, and Blood Institute (NHLBI)
Status: COMPLETED
Phase: Phase 1
Study type: INTERVENTIONAL

Acute Lymphoblastic Leukemia (ALL)Acute Myelogenous Leukemia (AML)Chronic Lymphocytic Leukemia (CLL)Chronic Myelogenous Leukemia (CML)MDS

Start date: 2014-08-26
Primary completion: 2018-05-23
Enrollment: 24

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.